Man City stays clear of United

By STUART CONDIE

AP Sports Writer

Associated Press Sports

updated 11:58 a.m. ET Oct. 29, 2011

LONDON (AP) -Manchester City stayed five points ahead of Manchester United at the top of the Premier League on Saturday, while Chelsea lost ground on the leaders with a 5-3 defeat against visiting Arsenal.

City overcame a second-half red card for Vincent Kompany to beat Wolverhampton Wanderers 3-1 and defending champion United won 1-0 at Everton, but the most notable result was at Stamford Bridge, where Robin van Persie scored a hat trick for the visiting Gunners.

Andre Santos and Theo Walcott got Arsenal's other goals as their club recorded its best win at Chelsea since 1934.

Also Saturday, Blackburn drew 3-3 with Norwich, Aston Villa drew 2-2 at Sunderland, Swansea beat Bolton 3-1 and Fulham won 2-0 at Wigan.

? 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


advertisement

More news
Man City stays clear of United

Manchester City stayed five points ahead of Manchester United at the top of the Premier League on Saturday, while Chelsea lost ground on the leaders with a 5-3 defeat against visiting Arsenal.

'Monster'?

Ex-U.S. coach Bob Bradley has the daunting challenge of reviving the hopes of the "monster'' of African football ? Egypt.

Source: http://nbcsports.msnbc.com/id/44131091/ns/sports-soccer/

cape coral fl friday night lights kansas city chiefs emmys emmys tom bosley christina hendricks

Auto Detailing And Automotive Paint Imperfections Removing ...

Since your automobile paint is the initial most evident characteristic of your automotive, then it?s worthwhile to invest enough time caring and maintaining for it to maintain it looking as if it is model new. Sadly though, loads of car owners have fell sufferer to defective paint jobs that make your car end up trying cheap and wasted. To treatment that, there are auto detailing companies that specialize on eradicating and correcting imperfections in your automobile paint.

Whether you are hiring a professional service for it or doing the repair yourself, below are some key info you need to know.

Use of Advantageous Compound

Using positive compound is commonly the default treatment for poor paint jobs. But earlier than you proceed additional, there are some eventualities whereby it?s not allowed until completely necessary. These include the following:

. moist spots and swirl marks . micro marring . paint restore mixing . excessive sun exposure . pitting from exhausting stones and sand . poor paint surface end

Cautious Detailing for Car Paint

When detailing your automobile, the usage of the precise tools and products make a huge difference with the standard of results. But other than the essential detailing materials, your hand is certainly one of your greatest tools. Some automated detailing jobs can be too harsh as to cause injury in your car, more than you initially came in with.

Be sure you take proper notes when making ready your compound. That is especially helpful in removing scratches and faulty paint jobs. Avoid masking off the trim for it should only increase your job significantly. Ensure to make use of compounds in the identical manner as you?d a sandpaper and keep away from making use of greater than 2? by 2? in a given area. But if you want to stick with spot therapy for scratches or uneven paint, then attempt to focus utility of compound within that given area.

Tips for Improved Compounding Outcomes

If you wish to enhance the general high quality of your car paint, you want to reckon about making use of the next thoughts for higher compounding results:

. Apply a slight brush of detailing spray onto the polishing pad since it?s going to make making use of the compound lots simpler and extra precise. Simply hold it damp (not wet) utilizing one quick shot.

. When applying paint on sharp edges of your automobile, ensure that to use it thinly. Keep away from using compound on these areas.

. Use a dense foam applicator for the compound since it?s a lot safer and simpler to handle with higher results.

. Avoid trying to minimize the looks of any imperfection on the paint job, say a scratch. If it is not that noticeable, it will be better to go away it alone instead of ruining the complete paint job.

Tremendous Polish and End

To utterly remove any imperfections and provides your automotive a groundbreaking new shine on its paint for a model-new look, then you may add polish as the ending touch. You have to know although that that is performed only for enhancement functions, but will not fix any imperfections in your automobile paint.

There are some basic hand automotive polishing strategies it?s essential to be taught to successfully carry out this job. The primary level behind automobile polishing is to make a finer texture on the paint floor previous to glazing. You will not want a sealant or wax to tell the pure gloss of the paint. The secret software here is a high quality foam applicator, which may be very efficient in buffing polish residue for a virtually brilliant look. You?ll quickly find out that it delivers a much more superior auto detailing outcome in the end.

In case you want additional facts with respect to paint protection for cars, pay a visit to Delia Graffertingz?s internet site without delay.

About Author

Author: KarineOrdas746

This author has published 37 articles so far. More info about the author is coming soon.

Related Posts

Source: http://www.usdems.org/auto-detailing-and-automotive-paint-imperfections-removing/

nor easter st.louis cardinals st.louis cardinals drag me to hell alot alot are you afraid of the dark

Kris Humphries ? I Was Robbed Blind by My Wedding Guest

Kim K's Hubby
I Was Robbed Blind
by My Wedding Guest!!

1028_kim_k_andrey_ex
Kim Kardashian
's husband claims he was bilked out of hundreds of thousands of dollars by a guy he invited to his wedding ... a guy who's been arrested for allegedly running a $1.7 million investment scam.

Andrey C. Hicks was a guest at Kim and Kris Humphries televised wedding bonanza in August ... and sat right behind the happy couple during the rehearsal dinner.

But TMZ has learned ... after the wedding, Kris learned Andrey was a target in a federal investigation in which he's suspected of raising money for a purported billion dollar hedge fund ... that didn't really exist.

Officials believe Andrey lied to several investors -- including Kris -- telling them, among other things, that he was a Harvard graduate ... when in fact, he was kicked out of the University after 3 semesters for crappy grades. Officials say Andrey only took 1 math class at Harvard ... and got a D-.

Officials claim 27-year-old Hicks stole $1.7 million from various investors ... and sources close to Kris tell us the NBA star accounted for hundreds of thousands of dollars himself.

Hicks was arrested in Canada on Friday and charged with wire fraud. Officials believe he was trying to flee to Switzerland. If convicted, Hicks could face up to 20 years in prison and a $250,000 fine.

Source: http://feedproxy.google.com/~r/RichGuysClub/~3/aE_zwnEeW5w/

boo tonga irb super bowl 2011 super bowl 2011 blackout blackout

Just Show Me: How to use Windows 7 desktop gadgets (Yahoo! News)

Welcome to?Just Show Me on Tecca TV, where we show you tips and tricks for getting the most out of the?gadgets in your life. In today's episode we'll show you how to use desktop gadgets in Windows 7.

With desktop gadgets you can put little widgets on your desktop that show you things like the weather outside or information about your computer's system status. It's a great way to have important information right on hand without opening up another application or webpage.

For more episodes of Just Show Me, subscribe to Tecca TV's YouTube channel and check out all our Just Show Me episodes. If you have any topics you'd like to see us cover, just drop us a line in the comments.

This article originally appeared on Tecca

More from Tecca:

Source: http://us.rd.yahoo.com/dailynews/rss/personaltech/*http%3A//news.yahoo.com/s/yblog_technews/20111027/tc_yblog_technews/just-show-me-how-to-use-windows-7-desktop-gadgets

john beck mariska hargitay gmcr

Michael Jackson: Defense of Dr. Conrad Murray stumbles at the start

Score one for the prosecution. A former physician for Michael Jackson, called as a defense witness, says he would "never" have administered propofol at a patient's home as sleep medicine.

Lawyers defending Michael Jackson?s personal physician sought Monday to poke holes in the prosecution?s case in the month-long manslaughter trial of Dr. Conrad Murray.

Skip to next paragraph

But the effort seemed to falter badly when a former physician for Mr. Jackson ? called as a defense witness ? testified that he would never, for any price, administer an intravenous sedative like propofol at a patient?s home as sleep medicine.

?Did you ever give Michael Jackson propofol,? Deputy District Attorney David Walgren asked Dr. Allan Metzger.

?Never,? Dr. Metger answered.

Was there any amount of money that would convince Dr. Metzger to administer propofol to Jackson in his house, Mr. Walgren asked.

"No,? the doctor said emphatically.

Rather than helping the defense, Metzger?s testimony appeared to significantly bolster the involuntary manslaughter case against Murray.

Murray is charged with giving Jackson a lethal dose of propofol on June 25, 2009 in an effort to treat the pop star?s chronic insomnia. The medical examiner ruled that Jackson died of acute propofol intoxication.

A medical expert called by the prosecution told the jury last week that the available evidence suggests that Murray set up an unimpeded intravenous drip of propofol that continued to flow into Jackson?s body until he was so drugged that he stopped breathing and died.

Defense lawyers ridiculed the assertion as mere opinion. But it remains to be seen whether Edward Chernoff and others on the defense team will offer a more plausible explanation for how so much of the powerful anesthetic got into Jackson?s system.

They have suggested that Jackson may have self-administered the lethal dose, but medical experts have said that prospect is unlikely because the anesthetic is so fast-acting.

Dr. Metzger?s testimony came shortly after Walgren announced that the prosecution was resting its case. So far, prosecutors have called 33 witnesses and introduced over 220 pieces of evidence at the trial at the Los Angeles County Courthouse.

Defense lawyers are expected to call 15 witnesses.

After the defense presents its case, prosecutors may call rebuttal witnesses before the case is submitted to the jury. The may happen as early as next week.

In addition to Metzger, the defense on Monday called four members of the Los Angeles Police Department and a nurse/practitioner who gave nutritional supplements and natural sleep remedies to Jackson intravenously in February and March 2009. The testimony of Cherilyn Lee is potentially significant because it demonstrates that Jackson was participating in nightly intravenous drips before the arrival of Dr. Murray in April.

Murray has said he provided propofol to Jackson on a nightly basis from April until his death in June.

Ms. Lee testified that at one point Jackson asked her to sit at his bedside through the night so she could observe his difficulty in staying asleep. She said she watched Jackson sleep for about five hours before he woke up around 3 a.m.

She said she had administered a special nutritional IV with a low dose of vitamin C, in addition to a cup of ?Sleepy Time Tea.?

?I stayed and watched him every second,? she told the jury.

Lee said Jackson had asked her to come to London and continue her nutritional therapy while on tour. But later Jackson complained that natural remedies would not ease his insomnia.

If convicted, Murray faces up to four years in prison and loss of his medical license.

The trial is set to continue on Tuesday.

Source: http://rss.csmonitor.com/~r/feeds/csm/~3/IaDAyNoZK68/Michael-Jackson-Defense-of-Dr.-Conrad-Murray-stumbles-at-the-start

zachary quinto zachary quinto koch brothers ashley judd brewers harbaugh the walking dead season 2

First, Eat All the Lawyers

We all worry about becoming obsolete; recently, my Slate colleague Farhad Manjoo sketched a frightening scenario in which robots take over industries like the law, medicine, even scientific discovery. The zombie apocalypse is the opposite scenario, in which our white-collar skills become worthless not through technical advance but through total system collapse. For blue-collar workers, the zombie stories are tales of comeuppance, of triumph: skills in auto maintenance, farming, plumbing, and electrical work?not to mention marksmanship?land blue-collar folks at the top of the new social order. This is not a bad thing, but it's nevertheless deeply disorienting to anyone who thought a college degree would mean never having to fix a generator.

Source: http://feeds.slate.com/click.phdo?i=4f75765b5b963007d9eed6cf0d14edfc

nfl scores world series tickets world series tickets nelson cruz nelson cruz michael young war of the worlds

Alibaba unveils W800, second-gen Aliyun phone, and unnamed 'cloud-powered' tablet

W800 and Aliyun tablet
In July we got our first taste of Aliyun OS, running on the W700. Now, with the Gregorian calendar year coming to a close, Alibaba is prepping its second wave "cloud-powered" hardware. First up is the W800, the successor to the original Aliyun handset. As far as specs go, the two look more or less the same -- with the latest version still rocking a 1GHz Tegra 2. The one obvious difference is the slightly larger 4.3-inch display gracing the front of the W800. Perhaps more interesting though, is the still unnamed tablet which also clearly bares NVIDIA branding. Speed and exact model of the CPU inside is anyone's guess, but we're assuming this isn't a Kal-el device. Price and release date for both are a mystery, but the W800 is expected to land sometime before November is out. Of course, you probably shouldn't expect these to show up in your local Best Buy, but you've got a friend in Hong Kong who can send you one, right?

Alibaba unveils W800, second-gen Aliyun phone, and unnamed 'cloud-powered' tablet originally appeared on Engadget on Tue, 25 Oct 2011 00:58:00 EDT. Please see our terms for use of feeds.

Permalink   |  sourceEngadget Chinese, 2  | Email this | Comments


Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/-x0UjuFmgHM/

wtc united 93 united 93 loose change pearl harbor the guard the guard

Linking of mutations in 12 genes to ovarian cancer may lead to more effective prevention

[ Back to EurekAlert! ] Public release date: 25-Oct-2011
[ | E-mail | Share Share ]

Contact: Leila Gray
leilag@u.washington.edu
206-685-0381
University of Washington

The study used a quick, accurate genome sequencing method that could become a single test to screen for a broad range of cancers

More patients with ovarian carcinoma carry cancer-predisposing mutations, and in more genes, than previously thought.

A rapid experimental method for screening genomes has located mutations in 12 genes for inherited cancers of the ovary, fallopian tubes and peritoneum (the thin tissue lining the lower abdomen).

More than one-fifth of ovarian cancers arise in women with a familial predisposition, but relying on family history would have missed one-third of the cases, said Dr. Elizabeth Swisher, senior author of a paper on these findings published online ahead of print in the Proceedings of the National Academy of Sciences.

Swisher is an associate professor of obstetrics and gynecology at the University of Washington in Seattle. She directs the Breast and Ovarian Cancer Prevention program at the UW and the Seattle Cancer Care Alliance, and is an affiliate researcher at the Fred Hutchinson Cancer Research Center.

The results of her most recent study have far reaching implications beyond the important identification of mutations linked to ovarian and related cancers.

The speedy, low-cost genome analysis method her team developed could soon be applicable to patient testing for a broad range of all known breast, ovarian, colon, pancreatic and melanoma gene mutations. A single test might be able to screen a patient for susceptibility to all these cancers.

Also, the great number of specimens that this method can analyze simultaneously could allow for large scale, population studies of cancer-causing mutations. Such studies would tell who is at risk for certain cancers and how to effectively target prevention.

The UW scientists named their sequencing method BROCA, after Paul Broca, a 19th century medical scientist who was among the first to describe inherited breast and ovarian cancer. BROCA, the researchers said, is highly sensitive and can find all classes of genetic mutations, including single substitutions, small insertions and deletions, and large rearrangements of genes.

"The BROCA test is not patented," the researchers said, and added that designs for its use in genetic studies are freely available.

At present, most tests for genes already known to be associated with breast and ovarian cancer, BRAC1 and BRAC2, are done by a lone company. The cost is about $4,000 for a non-comprehensive test accompanied by an additional test to find gene rearrangements.

As more cancer-susceptibility genes are found, it is not economical to test a person for one gene mutation, and then go back and test for another, then another. Gene-by-gene testing will eventually give way to a single test that accurately identifies all classes of those gene mutations that permit tumors to grow unchecked.

At present, the price for the BROCA chemicals is about $200. The costs are shrinking for running the genome analysis, due to the increasing number of samples that can be put through the multiple "lanes" in the sequencer.

Swisher and her team concentrated on ovarian cancer gene-detection in trying this sequencing method because ovarian cancer is one of the most deadly to affect a woman's reproductive system. It is difficult to diagnose in its early stages

Ovarian cancer and cancer of the peritoneum begin quietly. Eventually vague symptoms appear, but they mimic seemingly benign conditions, like bloating.

"Most women are not diagnosed until the cancer is has advanced to the point where the chances of a cure are small," Swisher said. "Women with early stage ovarian cancer have a better survival than those diagnosed with late stages, but current methods of detection are not effective."

The lack of effective early detection is why Swisher and her research team are looking for a more complete genetic picture of ovarian and related cancers. Learning the genetic mutations associated with these cancers could lead to tests to identify early on the women prone to these malignancies.

A quick, low cost, individual screening test for a variety of gene mutations linked to ovarian cancer would allow for effective preventive measures, the researchers said. For example, a woman whose genetic profile indicates high risk could consider an operation to remove her ovaries and fallopian types. This procedure has already been shown to decrease the overall death rate in women who have BRCA1 or BRAC2 mutations.

These particular mutations heighten the risk of ovarian as well as breast cancer. As this current study reveals, previously unknown mutations in other genes also occur in the population of women diagnosed with ovarian cancer.

New developments in cancer drugs that selectively wipe out cells containing certain genetic deficiencies is another major incentive for scientists to locate other mutations involved in ovarian cancer, Swisher noted. For example, the new drug class called poly-ADP-ribose polymerase (PARP) inhibitors is lethal to cells missing chemicals produced by normal BRAC1 and BRAC2 genes. The PARP drugs are showing efficacy in treating ovarian cancers in patients with mutations in these genes.

The UW scientists applied BROCA to analyze the DNA from a 360 women undergoing surgery between 2001 and 2010 at the University of Washington for cancer of the ovaries, peritoneum, or fallopian tubes, or who had cancer of the ovaries as well as the uterine lining. The women were enrolled at diagnosis. Neither age of onset of the cancer nor their family history were selection factors.

Among this group of women, the researchers found 85 mutations in 12 genes. Many were loss-of-function mutations. An example of loss of function is the inability of cells to produce chemicals to suppress tumors. As the scientists expected, women with a personal history of breast cancer had an extremely high likelihood of harboring an inherited mutation. Family history of breast, ovarian, uterine, and pancreatic cancer but not colon cancer were each associated with inherited mutations.

"An observation that has major implications for clinical practice was that nearly one-third of the women with inherited mutations had no prior personal history of breast cancer and no family history of ovarian or breast cancer," Swisher noted. This high proportion of unrecognized risk, she explained, is probably due to the combined effects of small family size, female cancer genes inherited from unaffected fathers, and the simple odds of a mutated gene being inherited or not inherited.

The researcher also found that the age when these types of cancer appear was not generally associated with the likelihood of having an inherited mutation, or with the gene in which a mutation was found.

There were no significant differences in survival rates between women who had one or more of the mutations identified in this study, and women who did not have these particular mutations.

What we found overall, the researchers noted, was that more than one in five cases of ovarian carcinoma were associate with a mutation in tumor suppressor genes. In their normal form, these genes act in a way that keeps tumors from growing.

The findings of this study, the researcher concluded, point to the need to develop comprehensive testing for inherited carcinoma for all women with ovarian, peritoneal or fallopian tube cancer, regardless of their age or family history. The researchers are moving clinical science forward to a time when expensive single gene testing for thousands of dollars will be replaced by testing many genes simultaneously at low cost.

###

In addition to Swisher, the scientists on this project were Tom Walsh, Silvia Casadei, Ming K. Lee, Anne Thornton, Wendy Roeb, Sunday M. Stray, and Mary-Claire King, all of the UW Division of Medical Genetics, Department of Medicine, and Christopher Pennil, Kathy Agnew, Anneka Wickramanayake, Barbara Norquist, and Kathryn Pennington, all of the UW Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Rochelle Garcia, UW Department of Pathology.

The study, "Mutations in 12 genes for inherited ovarian, Fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing," was funded by the National Institutes of Health, The Breast Cancer Research Foundation, Susan G. Komen for the Cure, and the U.S. Department of Defense Ovarian Cancer Research Program.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


[ Back to EurekAlert! ] Public release date: 25-Oct-2011
[ | E-mail | Share Share ]

Contact: Leila Gray
leilag@u.washington.edu
206-685-0381
University of Washington

The study used a quick, accurate genome sequencing method that could become a single test to screen for a broad range of cancers

More patients with ovarian carcinoma carry cancer-predisposing mutations, and in more genes, than previously thought.

A rapid experimental method for screening genomes has located mutations in 12 genes for inherited cancers of the ovary, fallopian tubes and peritoneum (the thin tissue lining the lower abdomen).

More than one-fifth of ovarian cancers arise in women with a familial predisposition, but relying on family history would have missed one-third of the cases, said Dr. Elizabeth Swisher, senior author of a paper on these findings published online ahead of print in the Proceedings of the National Academy of Sciences.

Swisher is an associate professor of obstetrics and gynecology at the University of Washington in Seattle. She directs the Breast and Ovarian Cancer Prevention program at the UW and the Seattle Cancer Care Alliance, and is an affiliate researcher at the Fred Hutchinson Cancer Research Center.

The results of her most recent study have far reaching implications beyond the important identification of mutations linked to ovarian and related cancers.

The speedy, low-cost genome analysis method her team developed could soon be applicable to patient testing for a broad range of all known breast, ovarian, colon, pancreatic and melanoma gene mutations. A single test might be able to screen a patient for susceptibility to all these cancers.

Also, the great number of specimens that this method can analyze simultaneously could allow for large scale, population studies of cancer-causing mutations. Such studies would tell who is at risk for certain cancers and how to effectively target prevention.

The UW scientists named their sequencing method BROCA, after Paul Broca, a 19th century medical scientist who was among the first to describe inherited breast and ovarian cancer. BROCA, the researchers said, is highly sensitive and can find all classes of genetic mutations, including single substitutions, small insertions and deletions, and large rearrangements of genes.

"The BROCA test is not patented," the researchers said, and added that designs for its use in genetic studies are freely available.

At present, most tests for genes already known to be associated with breast and ovarian cancer, BRAC1 and BRAC2, are done by a lone company. The cost is about $4,000 for a non-comprehensive test accompanied by an additional test to find gene rearrangements.

As more cancer-susceptibility genes are found, it is not economical to test a person for one gene mutation, and then go back and test for another, then another. Gene-by-gene testing will eventually give way to a single test that accurately identifies all classes of those gene mutations that permit tumors to grow unchecked.

At present, the price for the BROCA chemicals is about $200. The costs are shrinking for running the genome analysis, due to the increasing number of samples that can be put through the multiple "lanes" in the sequencer.

Swisher and her team concentrated on ovarian cancer gene-detection in trying this sequencing method because ovarian cancer is one of the most deadly to affect a woman's reproductive system. It is difficult to diagnose in its early stages

Ovarian cancer and cancer of the peritoneum begin quietly. Eventually vague symptoms appear, but they mimic seemingly benign conditions, like bloating.

"Most women are not diagnosed until the cancer is has advanced to the point where the chances of a cure are small," Swisher said. "Women with early stage ovarian cancer have a better survival than those diagnosed with late stages, but current methods of detection are not effective."

The lack of effective early detection is why Swisher and her research team are looking for a more complete genetic picture of ovarian and related cancers. Learning the genetic mutations associated with these cancers could lead to tests to identify early on the women prone to these malignancies.

A quick, low cost, individual screening test for a variety of gene mutations linked to ovarian cancer would allow for effective preventive measures, the researchers said. For example, a woman whose genetic profile indicates high risk could consider an operation to remove her ovaries and fallopian types. This procedure has already been shown to decrease the overall death rate in women who have BRCA1 or BRAC2 mutations.

These particular mutations heighten the risk of ovarian as well as breast cancer. As this current study reveals, previously unknown mutations in other genes also occur in the population of women diagnosed with ovarian cancer.

New developments in cancer drugs that selectively wipe out cells containing certain genetic deficiencies is another major incentive for scientists to locate other mutations involved in ovarian cancer, Swisher noted. For example, the new drug class called poly-ADP-ribose polymerase (PARP) inhibitors is lethal to cells missing chemicals produced by normal BRAC1 and BRAC2 genes. The PARP drugs are showing efficacy in treating ovarian cancers in patients with mutations in these genes.

The UW scientists applied BROCA to analyze the DNA from a 360 women undergoing surgery between 2001 and 2010 at the University of Washington for cancer of the ovaries, peritoneum, or fallopian tubes, or who had cancer of the ovaries as well as the uterine lining. The women were enrolled at diagnosis. Neither age of onset of the cancer nor their family history were selection factors.

Among this group of women, the researchers found 85 mutations in 12 genes. Many were loss-of-function mutations. An example of loss of function is the inability of cells to produce chemicals to suppress tumors. As the scientists expected, women with a personal history of breast cancer had an extremely high likelihood of harboring an inherited mutation. Family history of breast, ovarian, uterine, and pancreatic cancer but not colon cancer were each associated with inherited mutations.

"An observation that has major implications for clinical practice was that nearly one-third of the women with inherited mutations had no prior personal history of breast cancer and no family history of ovarian or breast cancer," Swisher noted. This high proportion of unrecognized risk, she explained, is probably due to the combined effects of small family size, female cancer genes inherited from unaffected fathers, and the simple odds of a mutated gene being inherited or not inherited.

The researcher also found that the age when these types of cancer appear was not generally associated with the likelihood of having an inherited mutation, or with the gene in which a mutation was found.

There were no significant differences in survival rates between women who had one or more of the mutations identified in this study, and women who did not have these particular mutations.

What we found overall, the researchers noted, was that more than one in five cases of ovarian carcinoma were associate with a mutation in tumor suppressor genes. In their normal form, these genes act in a way that keeps tumors from growing.

The findings of this study, the researcher concluded, point to the need to develop comprehensive testing for inherited carcinoma for all women with ovarian, peritoneal or fallopian tube cancer, regardless of their age or family history. The researchers are moving clinical science forward to a time when expensive single gene testing for thousands of dollars will be replaced by testing many genes simultaneously at low cost.

###

In addition to Swisher, the scientists on this project were Tom Walsh, Silvia Casadei, Ming K. Lee, Anne Thornton, Wendy Roeb, Sunday M. Stray, and Mary-Claire King, all of the UW Division of Medical Genetics, Department of Medicine, and Christopher Pennil, Kathy Agnew, Anneka Wickramanayake, Barbara Norquist, and Kathryn Pennington, all of the UW Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Rochelle Garcia, UW Department of Pathology.

The study, "Mutations in 12 genes for inherited ovarian, Fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing," was funded by the National Institutes of Health, The Breast Cancer Research Foundation, Susan G. Komen for the Cure, and the U.S. Department of Defense Ovarian Cancer Research Program.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2011-10/uow-lom102511.php

nebraska football the academy is the academy is colorado avalanche colorado avalanche bass lake michael jackson kids